Information about SaveRxCanada.to
List of countries where we can ship Evolocumab:
Latest news releases on Evolocumab:
Evolocumab (trade name Repatha) is a monoclonal antibody designed for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data. In two open-label, randomized trials
Anwendungsgebiet gemäß Fachinformation für Evolocumab (Repatha® ) Hypercholesterinämie und gemischte Dyslipidämie: Repatha wird bei Erwachsenen mit primärer Hypercholesterinämie (heterozygot familiär und nicht-familiär) oder gemischter Dyslipidämie zusätzlich zu diätetischer Therapie angewendet:
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. We conducted a randomized, double-blind, placebo
The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.
Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
2) Until recently (Ref 2), Evolocumab had been approved on the basis that it lowered cholesterol levels. There was no evidence that it had an impact on cardiovascular events or mortality.
Patients with higher baseline lipoprotein(a) levels have a greater reduction in cardiovascular events with the PSCK9 inhibitor evolocumab, suggesting potential pleiotropic effects, researchers say.
U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Contact FDA
Repatha® (evolocumab) is used with diet alone or with a statin as a treatment to lower high LDL cholesterol & reduce the risk of heart attack or stroke.